Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Feb 07, 2018 7:33pm

192 Views

Post# 27523170

RE:RE:RE:RE:Haven't posted for a while

I would add to that the question about if FDA was planning to revisit WuXi's installation site. The answer was: "Not at all"

jfm1330 wrote: Two key quotes from Tanguay in the CC

"This drug is going to make a difference for thousands of people with multi drug resistant HIV-1."

"Everything is in the hand of the FDA and we have'nt recieved any more questions for many many weeks at this time."